(Q44133715)

English

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Charlott Brunmark

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Anna Runström

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Lennart Ohlsson

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Birgitta Sparre

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Thomas Brodin

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Mikael Aström

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Gunnar Hedlund

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Journal of Neuroimmunology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

130

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

163-172

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic therapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide inhibits programmed cell death of peripheral T cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in hypothalamic corticotrophin-releasing factor and anterior pituitary pro-opiomelanocortin mRNA during the course of experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide enhances apoptosis in CD4+CD8+ thymocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic experimental autoimmune encephalomyelitis induced by the 89-101 myelin basic protein peptide in B10RIII (H2r) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1: from basic research to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease prom

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900225-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0165-5728(02)00225-4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44133715&oldid=2106949540"